
CYTK • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold CYTK in your mock portfolio yet.
Cytokinetics is currently unprofitable, as reflected by its negative EPS of -6.30 and a negative PE ratio of -10.57, which together indicate ongoing operating and/or R&D losses. This profile is typical of a development‑stage biotech, where value is driven more by pipeline and regulatory milestones than by current earnings. From a pure financial-performance standpoint, the lack of profitability and cash-generating operations is a headwind for the stock.
At $66.62, Cytokinetics is trading meaningfully above its 200‑day moving average of $49.58, signaling a strong intermediate‑term uptrend. The 4.5% gain over the last month and an RSI of 56.88 suggest positive momentum without signs of extreme overbought conditions. Technically, the setup appears constructive, with the price action confirming sustained investor interest.
Alternative data points show constructive signals, particularly in hiring and professional engagement. Job openings are up 120% month over month to 44, which often indicates expansion, investment in pipeline, or preparation for commercialization. Social media followings, especially on LinkedIn, are growing modestly, implying rising professional awareness and interest, while web traffic levels appear stable but not yet a major growth driver.
Cytokinetics presents a classic high‑risk, high‑reward biotech profile: technically strong and expanding operationally, but still fundamentally unprofitable. The stock’s price action and alternative data (notably hiring and LinkedIn growth) lean bullish, suggesting optimism about the company’s pipeline or upcoming catalysts. However, the negative earnings profile and reliance on future success rather than current cash flows temper the outlook to neutral overall.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: